BMO Capital Raises Price Target on Merck (MRK)
Pharmaceutical company Merck & Co., Inc. (MRK) had its price target raised by BMO Capital on Tuesday, as the analysts believe that the company has a number of exciting drugs currently in its clinical pipeline.
The analysts maintain an “Outperform” rating on MRK and now see shares reaching $54. This price target suggests an 11% upside to Monday’s closing price of $48.45.
Merck shares were down a fraction during morning trading on Tuesday. The stock is up +18.03% year-to-date.
The Bottom Line
Shares of Merck (MRK) have a dividend yield of 3.55% based on last night’s closing price of $48.45 and the company’s annualized dividend payout of $1.72 per share.
Merck & Co., Inc. (MRK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability